‘A few kinks in the system exist because we opted for the silver edition, but the company is working through these now,’ The team is now ramping up testing and is confident Clarity LIMS will grow alongside the company. Hudziec believes the whole process could have taken place within a month, but internal company verifications slowed final system customisation. ‘The system was logical and made sense, and the training helped us with back-end configurations, and customisation to fit our workflow.’īaby Gene’s LIMS has just gone live, with entire implementation taking two months. ‘These sessions were so useful we opted out of having someone from GenoLogics come here,’ said Hudziec. The team was on a tight deadline and wanted the system up and running within weeks, but didn’t want to lose too much manpower in the process.Ĭonsequently Hudziec and colleagues opted for webinar training sessions, across several weeks, giving them the chance to ‘play with the system’ and ask questions later.

LIMS implementation was quite straightforward. ‘The silver gave as a great option as a start-up lab, so we thought “Okay, this is something we can really afford and if we later transition to ‘gold’ all of the information entered into this LIMS will be transferred over”,’ explained Hudziec. Hudziec and colleagues looked at several systems, but GenoLogics actually offered a ‘silver’ and ‘gold’ package, and the team opted for the former, cheaper option. ‘A lot of things that we would have had to customise with a different system were already incorporated and after a demonstration we could see it made sense visually and fitted with our types of tests.’Ĭrucially, for this small start-up, Clarity LIMS was affordable. ‘Clarity LIMS is very next-generation sequencing focused and has just the type of genetic sequencing that we’re doing,’ said Hudziec.

For them, US-based GenoLogics’ Clarity LIMS, built for the needs of clinical or research genomics and mass spectrometry laboratories, was an obvious choice. While it’s still early days for the company, Hudziec and colleagues hope soon to be carrying out at least 1,000 tests a month, and for this, a LIMS is crucial. ‘But if you don’t, then this can have a lifetime impact.’ ‘Many conditions are treatable by, say, dietary supplement, if you catch them early,’ she added.

The clinical genetic test delivers information on any pathogenic or likely pathogenic variants within a newborn baby and, crucially, the clinical significance.Īs Dr Meghan Hudziec, one of Baby Gene’s three-strong team, explained: ‘We provide a supplementary screen to that offered to families in the US some states screen for fewer conditions than others. Baby Genes is a US-based start-up that uses next-generation sequencing to screen newborns for myriad conditions, from cystic fibrosis and sickle cell anaemia to the rarer Fabry and Gaucher diseases.

Iso 17025 gap analysis template